Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T22:13:13.107Z.
Calculation as of: 2026-10-06T22:13:13.107Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e64ee45e162b8fcb3c04564696a4f5631675aa9d571ebc51c9b2157b48bafcf8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Rani Therapeutics Holdings, Inc.
Market Cap
$54.14M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | $54.14M | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.70M | N/A |
| Aldeyra The (ALDX)vs › | $55.25M | N/A |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | N/A |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A |
| ImageneBio Inc (IMA)vs › | $51.88M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
